Browse the evidence

Older adults require higher total protein intakes (1.0–1.5 g/kg/d) and higher EAA/leucine density to overcome anabolic resistance and maximize muscle protein synthesis.

If you are over 65, aim for 1.0 to 1.5 grams of protein per kilogram of body weight daily. Focus on protein sources rich in essential amino acids, especially leucine, to help your muscles respond better to food and exercise. This helps prevent age-related muscle loss.

Semaglutide 2.4 mg once weekly is a highly effective treatment for obesity, leading to an average 14.9% body weight loss in nondiabetic adults over 68 weeks, and reduces major adverse cardiovascular events (MACE) in patients with obesity without diabetes.

Semaglutide 2.4 mg once weekly is a powerful treatment for obesity. In clinical trials, it helped people lose nearly 15% of their body weight. It also reduces the risk of major cardiovascular events in people with obesity but no diabetes. Discuss with your doctor if this once-weekly injection is right for you.

Semaglutide (2.4 mg once weekly) and Tirzepatide (up to 15 mg once weekly) produce significant weight loss (up to 14.9-20.9%) and improved glycemic control (HbA1c reduction >2%) in adults with obesity or type 2 diabetes, outperforming placebo and existing pharmacotherapies.

Semaglutide and Tirzepatide are highly effective, once-weekly injectable treatments for obesity and type 2 diabetes. They work by mimicking hormones that regulate appetite and blood sugar, leading to significant weight loss (up to 20%) and better glucose control than most other drugs. Because weight regain is common after stopping, these medications are intended for long-term management of these chronic conditions, not short-term fixes.

Tirzepatide produces substantial, dose-dependent weight loss in non-diabetic adults with obesity, with maximum tolerated doses achieving mean body weight reductions of approximately 20.9% compared to placebo.

If you have obesity and do not have diabetes, tirzepatide is a highly effective pharmacological intervention for weight loss. The medication works by mimicking hormones that regulate appetite and metabolism. Higher doses (up to the maximum tolerated dose) yield greater weight loss, with some patients losing over 20% of their body weight. While gastrointestinal side effects like nausea are common, they do not appear to increase the risk of serious health events compared to a placebo, making it a viable option for chronic weight management.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) produce significant, clinically meaningful weight loss (7–21%) and improve cardiometabolic markers in adults and adolescents with obesity.

If you have obesity, GLP-1 medications like semaglutide or tirzepatide are currently the most effective pharmacological tools available, producing weight loss comparable to bariatric surgery. They work by mimicking hormones that regulate appetite and digestion. While they require weekly (or daily) injections and can cause temporary gastrointestinal side effects, they also improve blood pressure, blood sugar, and cholesterol. Because obesity is a chronic disease, these medications are intended for long-term use to maintain weight loss, not just short-term fixes.

Discontinuation of GLP-1 receptor agonist therapy leads to substantial weight regain, indicating that obesity requires long-term, possibly lifelong, pharmacological management.

If you stop taking GLP-1 medications like semaglutide, you will likely regain most of the weight you lost. This is because obesity is a chronic condition, and the medication helps manage the underlying hormonal drivers. To keep the weight off, you likely need to stay on the medication long-term, similar to how blood pressure medication is used for hypertension.

Tirzepatide and semaglutide are the only obesity management medications (OMMs) achieving greater than 10% total body weight loss (TBWL) at study endpoints, with tirzepatide uniquely associated with a significantly higher proportion of patients achieving ≥25% TBWL.

If you are seeking significant, clinically meaningful weight loss (over 10% of body weight), current evidence strongly supports using tirzepatide or semaglutide over older oral medications. Tirzepatide shows the highest efficacy, with a unique ability to help a larger proportion of patients lose 25% or more of their body weight. Be aware that these are long-term treatments; stopping them typically leads to regaining most of the lost weight, so they should be viewed as ongoing management for obesity, not a short-term fix.

Tirzepatide induces significant, dose-dependent weight loss in patients with obesity or type 2 diabetes, with non-diabetic individuals experiencing greater absolute weight reduction than diabetic individuals at equivalent doses.

Tirzepatide is a highly effective treatment for weight loss, with higher doses (15 mg) producing the greatest results. Non-diabetic patients tend to lose more weight than diabetic patients at the same dose. The most common barrier is gastrointestinal side effects like nausea, which are dose-dependent but typically manageable and do not lead to serious health risks.

Tirzepatide increases the likelihood of achieving clinically meaningful weight loss thresholds (≥5%, ≥10%, ≥15%) in a dose-dependent manner, with 15 mg showing the highest odds ratios for all thresholds.

Higher doses of tirzepatide significantly increase your chances of losing 5%, 10%, or 15% of your body weight. The 15 mg dose offers the highest probability of achieving these milestones compared to lower doses.

Semaglutide (2.4 mg weekly) produces significantly greater weight loss than liraglutide (3.0 mg daily), orlistat, and phentermine in obese individuals.

If you have obesity or overweight with related health risks, Semaglutide (2.4 mg weekly) is currently the most effective pharmacological option for weight loss, significantly outperforming Liraglutide, Orlistat, and Phentermine. You must start at a low dose (0.25 mg) and increase it every 4 weeks to minimize stomach side effects. This medication works best when combined with diet and exercise changes.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant, dose-dependent weight loss and HbA1c reduction in overweight and obese adults with type 2 diabetes, with efficacy increasing at doses of 5mg, 10mg, and 15mg administered once weekly.

If you have type 2 diabetes and are overweight or obese, Tirzepatide is a highly effective, once-weekly injection that helps you lose significant weight and lower your blood sugar. The higher the dose (up to 15mg), the more weight you tend to lose. While you might experience side effects like nausea or diarrhea, especially at higher doses, most people get used to it. It is more effective than many existing obesity medications.

Tirzepatide administration significantly reduces body weight in overweight and obese individuals (BMI ≥28 kg/m²) compared to control, with the magnitude of weight loss being dose-dependent.

If you have a BMI of 28 or higher, Tirzepatide is a clinically proven option for significant weight loss. It works by mimicking hormones that regulate blood sugar and appetite. You take it as a once-weekly injection, starting at a low dose (2.5mg) and increasing to 5mg, 10mg, or 15mg depending on your response. Expect some gastrointestinal side effects like nausea or diarrhea, especially at higher doses, but most people tolerate it well. The higher the dose, the more weight you tend to lose.

Tirzepatide significantly reduces HbA1c levels in individuals with Type 2 Diabetes, with the effect being dose-dependent.

For those managing Type 2 Diabetes, Tirzepatide offers a powerful tool to lower blood sugar levels (HbA1c). It works by helping your pancreas release insulin when needed and stopping the liver from making too much sugar. Like with weight loss, higher doses lead to greater HbA1c reductions. This makes it a viable option for patients who need better glycemic control alongside weight management.

Once-weekly subcutaneous semaglutide (specifically the 2.4 mg dose) produces substantial, sustained weight loss (mean reduction ~14.9%) and significant improvements in cardiometabolic risk factors (HbA1c, lipids, blood pressure) in adults with overweight or obesity, with an acceptable safety profile characterized by mild-to-moderate gastrointestinal side effects.

If you have obesity or overweight with comorbidities, once-weekly semaglutide (2.4 mg) is a highly effective medical treatment that can help you lose nearly 15% of your body weight and improve heart health markers like blood pressure and cholesterol. While you may experience temporary stomach issues like nausea when starting, these usually get better as your body adjusts. It is not a quick fix but a long-term management tool for a chronic condition, comparable to how medication manages high blood pressure.

Weekly subcutaneous semaglutide (up to 1 mg) as an adjunct to automated insulin delivery significantly improves glycemic control (increasing time in range by 4.8 percentage points) and reduces body weight in adults with type 1 diabetes without increasing hypoglycemia risk.

If you have Type 1 Diabetes and use an automated insulin delivery system, adding weekly semaglutide (up to 1 mg) can significantly improve your time in range and help with weight loss without increasing the risk of low blood sugar. While gastrointestinal side effects are common, they are usually manageable, and the risk of ketosis, though present, can be mitigated with education and monitoring. This is a viable option, especially for those with higher BMI.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide induce significant weight loss (up to ~15%) in non-diabetic individuals with obesity, primarily by acting on GLP-1 receptors in the brain (specifically the arcuate nucleus and area postrema) to suppress food intake.

GLP-1 receptor agonists like semaglutide (2.4 mg weekly) are highly effective for weight loss in obese, non-diabetic adults, achieving ~15% body weight reduction. They work by suppressing appetite via brain receptors. Be aware of common side effects like nausea and the likelihood of weight regain if treatment stops, suggesting a need for long-term management.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce greater weight loss than GLP-1RAs alone (e.g., semaglutide) in both diabetic and non-diabetic populations, while potentially reducing nausea through GIP receptor signaling.

Tirzepatide (5-15 mg weekly) is more effective for weight loss than semaglutide in patients with type 2 diabetes, achieving 8.5-12.4% weight loss compared to 6.7% for semaglutide. It works by targeting both GIP and GLP-1 receptors, potentially offering a better side effect profile regarding nausea.

GLP-1 and GIP agonists (e.g., semaglutide) significantly improve glycemic control, promote weight loss, and provide cardiovascular and renal protection in patients with obesity and type 2 diabetes.

If you have obesity and type 2 diabetes, ask your doctor about GLP-1/GIP agonists. These drugs treat the underlying biology, help you lose weight, and protect your heart and kidneys.

GLP-1 receptor agonists lower plasma glucose and suppress appetite, providing significant benefits for glycemic control and weight loss in type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, GLP-1 receptor agonists are a proven, first-line treatment option that effectively lowers blood sugar and aids weight loss. Discuss these options with your healthcare provider to see if they are appropriate for your specific health profile.

GLP-1 receptor agonists promote significant weight loss in adults with obesity or overweight, with semaglutide 2.4 mg showing superior efficacy compared to placebo and other agents.

For significant weight loss, GLP-1 RAs like semaglutide (Wegovy) or tirzepatide (Zepbound/Mounjaro) are highly effective, producing 15% or more body weight loss in clinical trials. They work by reducing appetite and slowing digestion. While side effects like nausea are common, they often improve over time. These drugs are most effective when combined with lifestyle changes.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (up to 25%) and improve cardiometabolic health, including cardiovascular and renal outcomes.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss and heart health. They work by mimicking hormones that control hunger and metabolism. Discuss these options with your doctor if lifestyle changes alone haven't worked.

GLP-1 receptor agonists (semaglutide 2.4mg) and dual agonists (tirzepatide 15mg) produce significant, sustained weight loss (11.8% and 14.7-20.9% respectively) compared to placebo, but discontinuation leads to significant weight recurrence (approx. 2/3 of lost weight).

If you qualify (BMI ≥27 with comorbidity or ≥30), GLP-1 agonists like semaglutide (2.4mg weekly) or tirzepatide (15mg weekly) are highly effective, producing 12-21% weight loss. However, these are chronic treatments; stopping them leads to regaining ~2/3 of the weight. Discuss coverage and long-term commitment with your provider.

Semaglutide significantly reduces all-cause mortality and myocardial infarction risk in patients at increased risk of cardiovascular events, with high-certainty evidence.

If you are at high risk for heart issues, semaglutide is a proven treatment that lowers your risk of dying or having a heart attack. While you may experience stomach upset, these side effects are generally not serious and are outweighed by the life-saving benefits. Consult your doctor to see if this medication is appropriate for your specific risk profile.

Tirzepatide (5-15 mg) produces significantly greater weight loss, waist circumference reduction, and HbA1c improvement compared to placebo, insulin, and GLP-1 receptor agonists in adults with type 2 diabetes or obesity.

Tirzepatide is a highly effective treatment for weight loss and blood sugar control, outperforming existing GLP-1 drugs and insulin. It requires weekly injections and careful dose titration to manage gastrointestinal side effects like nausea.